Lung Cancer Molecular Biomarker Market (2026 - 2036)

Lung Cancer Molecular Biomarker Market Forecast and Outlook 2026 to 2036

Valuation of the global lung cancer molecular biomarker market is projected to grow from USD 5.4 billion in 2026 to USD 14.7 billion by 2036, registering a (CAGR) of 10.5%. This growth reflects increasing reliance on molecular profiling to guide targeted therapies, immunotherapy selection, and treatment response monitoring in lung cancer care.

Key Takeaways from Lung Cancer Molecular Biomarker Market

• Lung Cancer Molecular Biomarker Market Value (2026): USD 5.4 billion
• Lung Cancer Molecular Biomarker Market Forecast Value (2036): USD 14.7 billion
• Lung Cancer Molecular Biomarker Market Forecast CAGR: 10.5%
• Leading Product Category in Lung Cancer Molecular Biomarker Market: EGFR (27.0%)
• Key Growth Regions in Lung Cancer Molecular Biomarker Market: North America, Europe, Asia Pacific
• Key Players in Lung Cancer Molecular Biomarker Market: Roche Diagnostics GmbH, Thermo Fisher Scientific Inc., Qiagen N.V., Agilent Technologies Inc., Illumina Inc.

Molecular biomarker testing in lung cancer enables precise identification of actionable mutations such as EGFR, ALK, KRAS, and PD-L1, supporting personalized treatment strategies and improved clinical outcomes. These tests enhance diagnostic accuracy, reduce trial-and-error treatment approaches, and support early therapy optimization across diverse patient populations.

Genetic and genomic biomarker tests are expected to capture the leading share of the market in 2026, supported by widespread adoption of NGS and PCR-based assays within routine oncology workflows. Growing availability of companion diagnostics and expanding targeted drug pipelines continue to reinforce demand. Hospitals and diagnostic laboratories are projected to register the highest share of the lung cancer molecular biomarker market in 2026. Centralized testing infrastructure, access to advanced molecular platforms, and close integration with oncology care teams enable these settings to support high-volume testing, standardized reporting, and timely clinical decision-making, reinforcing sustained market growth.

Lung Cancer Molecular Biomarker Market

Category 

Segmental Analysis

By Product Type, Which Segment Holds the Dominant Share in the Lung Cancer Molecular Biomarker Market?

In terms of product type, EGFR segment leads the lung cancer molecular biomarker market with 27.0% share. Oncologists and diagnostic teams continue to rely heavily on EGFR testing due to its long-established clinical relevance, strong linkage with targeted therapies, and routine inclusion in lung cancer diagnostic protocols. EGFR assays remain a first-line requirement at diagnosis, supporting widespread and consistent demand across hospitals and cancer centers.

• Continued investment in assay sensitivity, faster turnaround times, and integration with molecular pathology workflows reinforces adoption across clinical settings.
• As treatment pathways increasingly depend on early and accurate mutation identification, EGFR biomarkers maintain a central role within lung cancer testing strategies, supporting confident therapy decisions and predictable clinical outcomes.

By Application, Which Segment Registers the Highest Share in the Lung Cancer Molecular Biomarker Market?

By application, therapy selection dominates the market with 49.0% share, highlighting the direct role of molecular biomarkers in guiding targeted therapy and immunotherapy choices. Biomarker-driven treatment selection reduces trial-based prescribing and improves response rates, making it a critical step in lung cancer care.

• Rising availability of targeted drugs and companion diagnostics continues to expand testing demand focused on treatment alignment.
• As precision oncology becomes standard practice, therapy selection remains the primary driver of biomarker testing, reinforcing its leadership within application segmentation and sustaining long-term market growth.

What are the Drivers, Restraints, and Key Trends of the Lung Cancer Molecular Biomarker Market?

• Drivers: Growing dependence on precision oncology and targeted treatment planning is driving adoption of lung cancer molecular biomarker testing across hospitals and diagnostic laboratories. Clinicians increasingly require accurate mutation profiling to guide therapy selection, monitor treatment response, and improve patient outcomes, making biomarker testing a routine part of lung cancer care.
• Restraint: High testing costs, limited access to advanced molecular platforms, and complexity of test interpretation restrict broader adoption in smaller hospitals and resource-limited settings. Variability in reimbursement coverage and need for specialized laboratory expertise further constrain market penetration.
• Trend 1: Increasing shift toward comprehensive NGS panels that enable simultaneous detection of multiple actionable mutations, supporting faster and more informed clinical decision-making.
• Trend 2: Growing focus on therapy-driven biomarker testing, where assays are closely aligned with targeted drugs and immunotherapies to improve treatment matching and clinical effectiveness.

Analysis of the Lung Cancer Molecular Biomarker Market by Key Country

The report covers an in-depth analysis of 30+ countries; top-performing countries are highlighted below.

What Factors Are Supporting Lung Cancer Molecular Biomarker Adoption in India?

India is expected to see growth at 12.2% CAGR, supported by expanding oncology infrastructure, rising awareness of biomarker-driven treatment, and improving access to molecular testing in metropolitan areas. Centralized diagnostic laboratories play a key role in scaling EGFR and NGS testing.

• Sales growth led by centralized diagnostic labs offering cost-optimized biomarker panels
• Rising demand for EGFR and NGS tests in metro-based cancer hospitals.

Why Is China a High-Growth Market for Lung Cancer Molecular Biomarkers?

China is projected to record a 12.1% CAGR, driven by rapid expansion of hospital oncology services, strong investment in molecular diagnostics, and growing use of targeted cancer therapies. Large hospitals and regional cancer centers are scaling NGS-based testing to support standardized lung cancer care.

• High sales momentum from large public hospitals scaling NGS-based lung cancer profiling
• Increasing test volumes supported by government-backed precision medicine programs

What Opportunities Can Lung Cancer Molecular Biomarker Companies Expect in the U.S.?

Revenue from lung cancer molecular biomarker testing in the U.S. is projected to grow at a 10.4% CAGR, driven by strong uptake of precision oncology, wide availability of targeted therapies, and routine use of biomarker testing at diagnosis. Hospitals and cancer centers increasingly rely on EGFR, KRAS, PD-L1, and NGS panels to guide treatment decisions. Favorable reimbursement and strong clinical guideline support continue to sustain demand across major oncology networks.

• Strong sales driven by routine use of molecular biomarkers at lung cancer diagnosis across major hospital networks
• High adoption of NGS panels and PD-L1 testing supports steady, high-value test volumes

What Opportunities Exist in Germany for Lung Cancer Molecular Biomarker Providers?

Germany is expected to grow at 10.2% CAGR, driven by advanced hospital diagnostics, strong reimbursement systems, and emphasis on precision oncology. Molecular testing is widely embedded in lung cancer treatment protocols, supporting stable and high-volume demand.

• Strong sales from hospital-based molecular diagnostics with high reimbursement coverage
• High testing volumes for comprehensive biomarker panels aligned with precision oncology

Why Is Lung Cancer Molecular Biomarker Demand Rising in the U.K.?

Lung cancer molecular biomarker testing in the UK is projected to expand at 10.1% CAGR, supported by centralized testing models, national cancer programs, and increasing use of targeted therapies. Integration of molecular diagnostics into public healthcare pathways supports consistent adoption.

• Centralized testing models drive consistent sales across public healthcare systems
• Increased use of NGS panels to support targeted and immunotherapy decisions

Competitive Landscape of the Lung Cancer Molecular Biomarker Market

Lung cancer molecular biomarker market is shaped by competition among global diagnostics leaders, molecular testing specialists, and genomics-focused technology providers. Companies focus on expanding biomarker portfolios, improving test accuracy, and strengthening integration with oncology workflows. Investment priorities include next-generation sequencing platforms, companion diagnostics development, bioinformatics capabilities, and scalable laboratory solutions to support growing precision oncology demand.

Market participants include Roche Diagnostics GmbH, Thermo Fisher Scientific Inc., Qiagen N.V., Agilent Technologies Inc., Illumina Inc. and other emerging molecular diagnostics providers. These companies offer biomarker assays covering EGFR, ALK, KRAS, PD-L1, and multi-gene NGS panels used for therapy selection and disease monitoring. Roche Diagnostics maintains strong presence through clinically validated assays aligned with targeted therapies. Thermo Fisher Scientific and Qiagen compete through broad molecular testing portfolios and strong laboratory integration. Illumina supports market growth through advanced sequencing platforms widely adopted in oncology testing.

Key Players in the Lung Cancer Molecular Biomarker Market

• Roche Diagnostics
• GmbH Thermo
• Fisher Scientific Inc.
• Qiagen
• N.V.Agilent Technologies Inc.
• Illumina Inc.

Bibliography

• World Health Organization, Cancer Diagnostics and Oncology Research Committee. (2023). Molecular biomarkers in lung cancer: Testing technologies, clinical integration, and quality standards. World Health Organization.
• International Organization for Standardization. (2023). In vitro diagnostic medical devices: Performance evaluation and quality management of molecular oncology assays (ISO Technical Report). ISO.
• European Committee for Standardization. (2022). Medical laboratories: Evaluation of molecular biomarker testing, quality control, and regulatory compliance in oncology diagnostics (EN Technical Report). CEN.
• Journal of Thoracic Oncology Editorial Board. (2024). Advances in lung cancer molecular biomarker testing, targeted therapy selection, and resistance monitoring. Journal of Thoracic Oncology, 19(4), 512-528.
• National Cancer Institute, Molecular Diagnostics Working Group. (2023). Guidelines for molecular profiling and biomarker-driven treatment in lung cancer. National Cancer Institute.